LYCOS RETRIEVER 
Organon: Companies
built 651 days ago
Organon and Ligand will share equally all costs for advertising and promotion, medical affairs and clinical trials. Each company is responsible for its own sales force costs and other expenses. Both companies have made significant commitments to conduct a minimum number of sales calls, with AVINZA in primary or secondary position, over the term of the agreement.
Source:
Under the agreement, both Organon and Pharmacopeia will work collaboratively to generate development compounds addressing targets of mutual interest by taking advantage of the complementary discovery skills and expertise of each company. The goal is to produce compounds ready to enter development which will be primarily handled by Organon. The agreement provides Pharmacopeia the option to co-develop and co-commercialize therapeutic candidates discovered through the alliance.
Source:
Eliot Feld brings his eclectic style to the New York City Ballet with his newest work, Organon, a complex and expansive ballet. Led by Damian Woetzel, Maria Kosrowski and Charles Askegaard and powered by some 63 dancers, thirty of whom are students from the School of American Ballet, Organon is choreographed to the organ music of Johannes Sebastian Bach. In order to create the vast sound which Feld wanted to fill the space of the New York State Theater, a specially commisioned system was built for the ballet by the Walker Technical Company. Last summer, Walker installed electrical organ "voices" into the instrument at the Fifth Avenue Presbyterian Church in New York to some controversy.
Source:
This news release contains certain forward-looking statements by Ligand and Organon that involve risks and uncertainties and reflect the companies' judgment as of the date of this release. These statements include those related to co-promotion implementation, sales and market growth, product potential and success, EPS, share of voice and number of sales representatives, and the option to extend the agreement. Actual events or results may differ from the companies' expectations. For example, there can be no assurance that co-promotion will be successful or that AVINZA sales will meet expectations. Additional information concerning these and other risk factors affecting Ligand's and Organon's businesses can be found in prior press releases as well as in the companies' public periodic filings with the Securities and Exchange Commission, available via the companies' respective internet sites. Ligand and Organon disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.
Source:
MORE ABOUT
Companies